Search

Catherine M Sylvain

from San Mateo, CA
Age ~54
Get Report
Also known as:
Catherine G Sylvain, Catherine S Morrow, Catherine Sylain, Cathie Sylvain, Cathy Sylvain
Phone and address:
240 Hobart Ave, San Mateo, CA 94402
Related to:
Trent L WatkinsBradley Anderson, 67Nancy J Fox, 70Kathleen Leach, 45Clifford SmithRuth Smith
Connected to:
Audrey G Sylvain, 74Deborah L Sylvain, 66Elude Sylvain, 53Francis Sylvain, 32Harold P Sylvain, 100Jamila Sylvain, 37Jan K Sylvain, 76Jasmin I Sylvain, 29Kaitlyn R Sylvain, 32Larry O Sylvain, 85

Catherine Sylvain Phones & Addresses

  • 240 Hobart Ave, San Mateo, CA 94402
  • 24 Prague St, San Mateo, CA 94401 (650) 375-8910
  • 2134 Shelter Creek Ln, San Bruno, CA 94066 (650) 866-3607
  • 1425 Bellevue Ave, Burlingame, CA 94010 (650) 375-8910
  • South San Francisco, CA

Work

Company: Genentech Aug 1, 2014 Position: Senior global project manager

Education

School / High School: Stanford University 1999 to 2000

Skills

Drug Development • Oncology • Pharmaceutical Industry • Lifesciences • Biotechnology • Drug Discovery • Chemistry • Clinical Development • Regulatory Submissions • Clinical Trials • Organic Chemistry • Medicinal Chemistry • Biopharmaceuticals • Gmp • Technology Transfer • Cro • Project Management • Cmc • Ind • Fda • Sop • Glp • Assay Development • Life Sciences

Industries

Pharmaceuticals

Professional Records

License Records

Catherine Mae Sylvain

License #:
004281-24 - Expired
Category:
Nursing Assistant
Issued Date:
Jul 4, 1992
Expiration Date:
Jul 5, 1993
Type:
Licensed Nursing Assistant

Catherine Mae Sylvain

License #:
004281-24 - Expired
Category:
Nursing Assistant
Issued Date:
Jul 4, 1992
Expiration Date:
Jul 5, 1993
Type:
Licensed Nursing Assistant

Resumes

Resumes

Catherine Sylvain Photo 1

Senior Global Project Manager

View page
Location:
San Francisco, CA
Industry:
Pharmaceuticals
Work:
Genentech
Senior Global Project Manager
Fibrogen, Inc. Jul 2013 - Jul 2014
Associate Director, Project Management For Cmc
Fibrogen, Inc. Oct 2010 - Jul 2014
Senior Manager, Project Management For Cmc
Macusight, Inc. Oct 2009 - Feb 2010
Project Manager
Proteolix Oct 2007 - Oct 2009
Senior Manager Chemical Development and Cmc Project Manager
Education:
Stanford University 1999 - 2000
University of California, Berkeley
Université Louis Pasteur (Strasbourg I)
Skills:
Drug Development
Oncology
Pharmaceutical Industry
Lifesciences
Biotechnology
Drug Discovery
Chemistry
Clinical Development
Regulatory Submissions
Clinical Trials
Organic Chemistry
Medicinal Chemistry
Biopharmaceuticals
Gmp
Technology Transfer
Cro
Project Management
Cmc
Ind
Fda
Sop
Glp
Assay Development
Life Sciences

Publications

Us Patents

2,4-Pyrimidinediamine Compounds And Their Uses

View page
US Patent:
7329671, Feb 12, 2008
Filed:
Jun 8, 2005
Appl. No.:
11/148746
Inventors:
Rajinder Singh - Belmont CA, US
Ankush Argade - Foster City CA, US
Donald Payan - Hillsborough CA, US
Susan Molineaux - San Mateo CA, US
Sacha J. Holland - San Francisco CA, US
Jeffrey Clough - Redwood City CA, US
Holger Keim - Menlo Park CA, US
Somasekhar Bhamidipati - Foster City CA, US
Catherine Sylvain - Burlingame CA, US
Hui Li - Millbrae CA, US
Alexander B. Rossi - San Francisco CA, US
Assignee:
Rigel Pharmaceuticals, Inc. - South San Francisco CA
International Classification:
A01N 43/54
A01K 31/55
US Classification:
514275, 544323
Abstract:
The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

2,4-Pyrimidinediamine Compounds And Their Uses

View page
US Patent:
7329672, Feb 12, 2008
Filed:
Jun 8, 2005
Appl. No.:
11/149105
Inventors:
Rajinder Singh - Belmont CA, US
Ankush Argade - Foster City CA, US
Donald Payan - Hillsborough CA, US
Susan Molineaux - San Mateo CA, US
Sacha J. Holland - San Francisco CA, US
Jeffrey Clough - Redwood City CA, US
Holger Keim - Menlo Park CA, US
Somasekhar Bhamidipati - Foster City CA, US
Catherine Sylvain - Burlingame CA, US
Hui Li - Millbrae CA, US
Alexander B. Rossi - San Francisco CA, US
Assignee:
Rigel Pharmaceuticals, Inc. - South San Francisco CA
International Classification:
A01N 43/54
A01K 31/505
US Classification:
514275, 544323
Abstract:
The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

2,4-Pyrimidinediamine Compounds And Their Uses

View page
US Patent:
7332484, Feb 19, 2008
Filed:
Jun 8, 2005
Appl. No.:
11/149418
Inventors:
Rajinder Singh - Belmont CA, US
Ankush Argade - Foster City CA, US
Donald Payan - Hillsborough CA, US
Susan Molineaux - San Mateo CA, US
Sacha J. Holland - San Francisco CA, US
Jeffrey Clough - Redwood City CA, US
Holger Keim - Menlo Park CA, US
Somasekhar Bhamidipati - Foster City CA, US
Catherine Sylvain - Burlingame CA, US
Hui Li - Millbrae CA, US
Alexander B. Rossi - San Francisco CA, US
Assignee:
Rigel Pharmaceuticals, Inc. - South San Francisco CA
International Classification:
A61K 31/535
US Classification:
5142305, 514275, 514105, 544323, 544324
Abstract:
The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

2,4-Pyrimidinediamine Compounds And Their Uses

View page
US Patent:
7435814, Oct 14, 2008
Filed:
Dec 8, 2005
Appl. No.:
11/299207
Inventors:
Rajinder Singh - Belmont CA, US
Ankush Argade - Foster City CA, US
Donald Payan - Hillsborough CA, US
Susan Molineaux - San Mateo CA, US
Sacha J. Holland - San Francisco CA, US
Jeffrey Clough - Redwood City CA, US
Holger Keim - Menlo Park CA, US
Somasekhar Bhamidipati - Foster City CA, US
Catherine Sylvain - Burlingame CA, US
Hui Li - Millbrae CA, US
Alexander B. Rossi - San Francisco CA, US
Assignee:
Rigel Pharmaceuticals, Inc. - South San Francisco CA
International Classification:
C07D 403/00
US Classification:
544295, 544324, 544105, 544 48
Abstract:
The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

Methods Of Treating Or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds

View page
US Patent:
7452879, Nov 18, 2008
Filed:
Oct 5, 2006
Appl. No.:
11/539147
Inventors:
Rajinder Singh - Belmont CA, US
Ankush Argade - Foster City CA, US
Hui Li - Millbrae CA, US
Somasekhar Bhamidipati - Foster City CA, US
David Carroll - San Francisco CA, US
Catherine Sylvain - San Mateo CA, US
Jeffrey Clough - Redwood City CA, US
Holger Keim - Menlo Park CA, US
Assignee:
Rigel Pharmaceuticals, Inc. - South San Francisco CA
International Classification:
C07D 401/14
C07D 403/14
C07D 413/14
C07D 417/14
A61K 31/506
A61K 31/4523
A61K 31/5377
A61K 31/541
A61P 19/02
A61P 37/00
US Classification:
5142315, 514272, 514274, 51425213, 5142272, 51421001, 51421101, 51421201, 544320, 544323, 544324, 544111, 544 60, 540484, 540450
Abstract:
The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.

2,4-Pyrimidinediamine Compounds And Their Uses

View page
US Patent:
7485724, Feb 3, 2009
Filed:
Oct 5, 2006
Appl. No.:
11/539054
Inventors:
Rajinder Singh - Belmont CA, US
Ankush Argade - Foster City CA, US
Donald Payan - Hillsborough CA, US
Susan Molineaux - San Mateo CA, US
Sacha J. Holland - San Francisco CA, US
Jeffrey Clough - Redwood City CA, US
Holger Keim - Menlo Park CA, US
Somasekhar Bhamidipati - Foster City CA, US
Catherine Sylvain - Burlingame CA, US
Hui Li - Millbrae CA, US
Alexander B. Rossi - San Francisco CA, US
Assignee:
Rigel Pharmaceuticals, Inc. - South San Francisco CA
International Classification:
C07D 239/02
US Classification:
544323, 544324
Abstract:
The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

2,4-Pyrimidinediamine Compounds And Their Uses

View page
US Patent:
7498435, Mar 3, 2009
Filed:
Oct 5, 2006
Appl. No.:
11/539018
Inventors:
Rajinder Singh - Belmont CA, US
Ankush Argade - Foster City CA, US
Donald Payan - Hillsborough CA, US
Susan Molineaux - San Mateo CA, US
Sacha J. Holland - San Francisco CA, US
Jeffrey Clough - Redwood City CA, US
Holger Keim - Menlo Park CA, US
Somasekhar Bhamidipati - Foster City CA, US
Catherine Sylvain - Burlingame CA, US
Hui Li - Millbrae CA, US
Alexander B. Rossi - San Francisco CA, US
Assignee:
Rigel Pharmaceuticals, Inc. - South San Francisco CA
International Classification:
C07D 239/02
US Classification:
544323, 544324
Abstract:
The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

Methods Of Treating Or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds

View page
US Patent:
7517886, Apr 14, 2009
Filed:
Jul 29, 2003
Appl. No.:
10/631029
Inventors:
Rajinder Singh - Belmont CA, US
Ankush Argade - Foster City CA, US
Donald G. Payan - Hillsborough CA, US
Jeffrey Clough - Redwood City CA, US
Holger Keim - Menlo Park CA, US
Somasekhar Bhamidipati - Foster City CA, US
Catherine Sylvain - Burlingame CA, US
Hui Li - Millbrae CA, US
Assignee:
Rigel Pharmaceuticals, Inc. - South San Francisco CA
International Classification:
A61K 31/4965
US Classification:
514256, 514825, 514903
Abstract:
The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.
Control profile
Catherine M Sylvain from San Mateo, CA, age ~54 Get Report